


96535

JOHN J. HOFFMAN  
ACTING ATTORNEY GENERAL OF NEW JERSEY  
Division of Law, 5<sup>th</sup> Floor  
124 Halsey Street  
P.O. Box 45029  
Newark, New Jersey 07101



By: Megan Cordoma  
Deputy Attorney General  
(973) 648-3453

STATE OF NEW JERSEY  
DEPARTMENT OF LAW & PUBLIC SAFETY  
DIVISION OF CONSUMER AFFAIRS  
STATE BOARD OF PHARMACY

IN THE MATTER OF THE : **Administrative Action**  
PERMIT OF :  
 : **INTERIM CONSENT ORDER**  
**LIBERTY DRUG AND SURGICAL** :  
PERMIT #28RS00390900 :  
 :  
TO OPERATE AS A PHARMACY :  
IN THE STATE OF NEW JERSEY :

This matter was opened to the New Jersey State Board of Pharmacy (the "Board") upon the receipt of an inspection report of Liberty Drug and Surgical ("Liberty"), located at 195 Main Street, Chatham, New Jersey. The report was dated September 26, 2013, and documents violations of the Board's regulations regarding sterile compounding as well as the requirements set forth in Chapter <797> of the United States Pharmaceutical Convention ("USP").

By Consent Order filed on December 19, 2013, Liberty agreed to immediate cessation of all sterile compounding and to

contract with a third-party monitor (the "Monitor") pre-approved by the Board to review all compounding operations of the pharmacy. The Monitor has now furnished the Board with a report demonstrating review of all processes and procedures, and attesting to compliance with all Board regulations and USP standards including environmental testing, pressure differential monitoring, and air and surface sampling for bacteria and fungi.

The parties, having agreed to entry of this Interim Order, without further formal proceedings, and Liberty, having agreed and given voluntary consent to the within Order and waiving any right to a hearing, and the Board finding the within disposition adequately protective of the public health, safety and welfare, and other good cause having been shown;

**IT IS, therefore, on this 31<sup>ST</sup> day of JANUARY, 2014**

**ORDERED THAT:**

1. Liberty may recommence all sterile compounding operations.

2. Liberty shall contract with a Monitor pre-approved by the Board to review all compounding operations of the pharmacy on at least two occasions before February 1, 2015 to ensure the pharmacy continues to be in compliance with the requirements of USP and the regulations of the Board. The Monitor shall evaluate Liberty at unannounced visits and provide comprehensive reports to the Board at approximately six month intervals.

3. All costs associated with the monitoring outlined in this Order shall be the responsibility of, and paid directly by, Liberty.


4. This Consent Order shall not be construed to be a disciplinary action or sanction of any kind, nor as an admission of liability of the pharmacy.

5. The entry of within Order is without prejudice to the further investigation and/or prosecution by the Board, the Attorney General, or any other regulatory or law enforcement agency of any violations by Liberty of any statutes or regulations governing the practice of pharmacy in the State of New Jersey or any violations of law, including but not limited to any pending matters under investigation and any violations that may be revealed by the Monitor's reports.

NEW JERSEY STATE BOARD OF PHARMACY

By:   
Thomas F.X. Bender, R.Ph.  
President

I have read the within Order and understand it. I agree to be bound by its terms and hereby consent to it being entered by the New Jersey Board of Pharmacy.

  
Alan R. Brown, Owner and RPIC  
Liberty Drug and Surgical

Dated: 1/31/14